Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung bipolarer affektiver Störungen

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

Zusammenfassung

Die Komplexität der Behandlung bipolarer affektiver Störungen ergibt sich daraus, dass im Krankheitsverlauf fünf verschiedene Symptomkonstellationen auftreten können (Depression, Hypomanie, Manie, gemischte Episode, Rapid Cycling), was oft zu einer polypharmazeutischen Therapie führt. So muss mehr als bei der Behandlung jeder einzelnen Episode der langfristige Verlauf und dessen besondere polare Natur berücksichtigt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Armani F, Andersen ML, Galduróz JC (2014) Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology (Berl) 231(4):639–649

    Article  CAS  Google Scholar 

  • Bowden CL, Singh V, Weisler R (2012) Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 126(5):342–350

    Article  CAS  PubMed  Google Scholar 

  • Cipriani A, Barbui C, Salanti G et al (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 378(9799):1306–1315

    Article  CAS  Google Scholar 

  • Cipriani A, Reid K, Young AH et al (2013) Valproic acid, valproate and divalproex in the main tenance treatment of bipolar disorder. Cochrane Database Syst Rev 10:CD003196

    Google Scholar 

  • Citrome L, Ketter TA, Cucchiaro J et al (2014) Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 155:20–27

    Article  CAS  PubMed  Google Scholar 

  • Crump C, Sundquist K, Winkleby MA et al (2013) Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70(9):931–939

    Article  PubMed  Google Scholar 

  • DGBS e.V., DGPPN e.V (2012) S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.0, Mai 2012

    Google Scholar 

  • Ghaemi SN, Ostacher MM, El-Mallakh RS et al (2010) Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71(4):372–380

    Article  PubMed  Google Scholar 

  • Goss AJ, Kaser M, Costafreda SG et al (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74(11):1101–1107

    Article  CAS  PubMed  Google Scholar 

  • Grover S, Kukreti R (2014) HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24(2):94–112

    Article  CAS  PubMed  Google Scholar 

  • Grunze H, Vieta E, Goodwin GM et al (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14(3):154–219

    Article  PubMed  Google Scholar 

  • Fountoulakis KN, Kasper S, Andreassen O et al (2012) Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262(Suppl 1):1–48

    Article  PubMed  Google Scholar 

  • Leon AC, Solomon DA, Li C et al (2012) Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry 169(3):285–291

    Article  PubMed Central  PubMed  Google Scholar 

  • Li CT, Bai YM, Huang YL et al (2011) Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 200(1):45–51

    Article  PubMed  Google Scholar 

  • Loebel A, Cucchiaro J, Silva R et al (2014a) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171(2):160–168

    Article  Google Scholar 

  • Loebel A, Cucchiaro J, Silva R et al (2014b) Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171(2):169–177

    Article  Google Scholar 

  • McIntyre RS, McElroy SL, Eudicone JM et al (2011) A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord 13(6)

    Google Scholar 

  • McKnight RF, Adida M, Budge K (2012) Lithium toxicity profile: a systematic review and meta-analysis. The Lancet 379(9817):721–728

    Article  CAS  Google Scholar 

  • Merikangas KR, Jin R, He JP et al (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68(3):241–251

    Article  PubMed Central  PubMed  Google Scholar 

  • Naughton M, Clarke G, O’Leary OF et al (2014) A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 156:24–35

    Article  CAS  PubMed  Google Scholar 

  • Pacchiarotti I, Bond DJ, Baldessarini RJ et al (2013) The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170(11):1249–1262

    Article  PubMed Central  PubMed  Google Scholar 

  • Parikh SV, LeBlanc SR, Ovanessian MM (2010) Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Can J Psychiatry 55(3):136–143

    PubMed  Google Scholar 

  • Post RM, Leverich GS, Altshuler LL et al (2012) Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry 73(7):924–930

    Article  PubMed  Google Scholar 

  • Viktorin A, Lichtenstein P, Thase ME et al (2014) The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. doi: 10.1176/appi.ajp.2014.13111501 (Epub ahead of print)

    PubMed  Google Scholar 

  • Yatham LN, Fountoulakis KN, Rahman Z et al (2013) Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 147(1–3):365–372

    Article  CAS  PubMed  Google Scholar 

  • Young AH, McElroy SL, Bauer M et al; EMBOLDEN I (Trial 001) Investigators (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71(2): 150–162

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mainz

    O. Benkert

Authors
  1. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Benkert, O. (2015). Medikamente zur Behandlung bipolarer affektiver Störungen. In: Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54769-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54769-0_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54768-3

  • Online ISBN: 978-3-642-54769-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation